| Year |
Citation |
Score |
| 2022 |
Walker J, Albert J, Liang D, Sun J, Schutzman R, Kumar R, White C, Beck-Broichsitter M, Schwendeman SP. In vitro degradation and erosion behavior of commercial PLGAs used for controlled drug delivery. Drug Delivery and Translational Research. PMID 35672653 DOI: 10.1007/s13346-022-01177-8 |
0.536 |
|
| 2021 |
Sun J, Walker J, Beck-Broichsitter M, Schwendeman SP. Correction to: Characterization of commercial PLGAs by NMR spectroscopy. Drug Delivery and Translational Research. PMID 34553336 DOI: 10.1007/s13346-021-01061-x |
0.444 |
|
| 2021 |
Sun J, Walker J, Beck-Broichsitter M, Schwendeman SP. Characterization of commercial PLGAs by NMR spectroscopy. Drug Delivery and Translational Research. PMID 34415565 DOI: 10.1007/s13346-021-01023-3 |
0.538 |
|
| 2021 |
Sun J, Hong Z, Shao S, Li L, Yang B, Hou Y, Wang H, Xu Y, Zhang Q, Pi J, Fu J. Liver-specific Nrf2 deficiency accelerates ethanol-induced lethality and hepatic injury in vivo. Toxicology and Applied Pharmacology. 115617. PMID 34116071 DOI: 10.1016/j.taap.2021.115617 |
0.397 |
|
| 2017 |
Fu J, Zheng H, Cui Q, Chen C, Bao S, Sun J, Li L, Yang B, Wang H, Hou Y, Xu Y, Xu Y, Zhang Q, Pi J. Nfe2l1 silenced insulinoma cells acquire aggressiveness and chemo-resistance. Endocrine-Related Cancer. PMID 29203613 DOI: 10.1530/ERC-17-0458 |
0.449 |
|
| 2017 |
Cui Q, Fu J, Hu Y, Li Y, Yang B, Li L, Sun J, Chen C, Sun G, Xu Y, Zhang Q, Pi J. Deficiency of long isoforms of Nfe2l1 sensitizes MIN6 pancreatic β cells to arsenite-induced cytotoxicity. Toxicology and Applied Pharmacology. PMID 28549828 DOI: 10.1016/j.taap.2017.05.013 |
0.447 |
|
| 2016 |
Incecayir T, Sun J, Tsume Y, Xu H, Gose T, Nakanishi T, Tamai I, Hilfinger J, Lipka E, Amidon GL. Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue. Journal of Pharmaceutical Sciences. 105: 925-34. PMID 26869437 DOI: 10.1016/J.Xphs.2015.11.036 |
0.697 |
|
| 2013 |
Sabit H, Dahan A, Sun J, Provoda CJ, Lee KD, Hilfinger JH, Amidon GL. Cytomegalovirus protease targeted prodrug development. Molecular Pharmaceutics. 10: 1417-24. PMID 23485093 DOI: 10.1021/Mp3007067 |
0.688 |
|
| 2011 |
Gupta SV, Gupta D, Sun J, Dahan A, Tsume Y, Hilfinger J, Lee KD, Amidon GL. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Molecular Pharmaceutics. 8: 2358-67. PMID 21905667 DOI: 10.1021/Mp200291X |
0.71 |
|
| 2011 |
Sun J, Miller JM, Beig A, Rozen L, Amidon GL, Dahan A. Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality. Expert Opinion On Drug Metabolism & Toxicology. 7: 313-23. PMID 21235283 DOI: 10.1517/17425255.2011.550875 |
0.535 |
|
| 2010 |
Sun J, Dahan A, Walls ZF, Lai L, Lee KD, Amidon GL. Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Molecular Pharmaceutics. 7: 2362-8. PMID 21028903 DOI: 10.1021/Mp100300K |
0.62 |
|
| 2010 |
Sun J, Dahan A, Amidon GL. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. Journal of Medicinal Chemistry. 53: 624-32. PMID 19957998 DOI: 10.1021/Jm9011559 |
0.586 |
|
| 2008 |
Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, Amidon GL. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules (Basel, Switzerland). 13: 1441-54. PMID 18719516 DOI: 10.3390/Molecules13071441 |
0.688 |
|
| Show low-probability matches. |